

# Michael P. Dorsch, PharmD, MS, FCCP, FAHA, FACC, BCCP

## Business Address

University of Michigan College of Pharmacy  
428 Church Street  
Ann Arbor, MI 48109  
Phone: 734-647-1452

---

## Professional Experience

- 2021-Present **Associate Professor with Tenure**  
College of Pharmacy, University of Michigan, Ann Arbor, MI
- 2018-2021 **Assistant Professor (tenure track)**  
College of Pharmacy, University of Michigan, Ann Arbor, MI
- 2014-2018 **Clinical Associate Professor**  
College of Pharmacy, University of Michigan, Ann Arbor, MI
- 2007-2018 **Director, PGY2 Cardiology Specialty Residency**  
Department of Pharmacy Services, University of Michigan Health System, Ann Arbor, MI
- 2005-Present **Clinical Pharmacist, Cardiology**  
Department of Pharmacy Services, University of Michigan Health System, Ann Arbor, MI
- 2012-2014 **Clinical Assistant Professor**  
College of Pharmacy, University of Michigan, Ann Arbor, MI
- 2007-2012 **Adjunct Clinical Assistant Professor**  
College of Pharmacy, University of Michigan, Ann Arbor, MI
- 2006-2009 **Preceptor, ACCP Heart Failure Traineeship**  
Department of Pharmacy Services, University of Michigan Health System, Ann Arbor, MI
- 2005-2007 **Adjunct Clinical Instructor**  
College of Pharmacy, University of Michigan, Ann Arbor, MI
- 2004-2005 **Clinical Instructor**  
Division of Pharmacotherapy and Experimental Therapeutics  
School of Pharmacy, University of North Carolina, Chapel Hill, NC
- 2004-2005 **Pharmacist**  
Department of Pharmacy, University of North Carolina Hospitals, Chapel Hill, NC
- 2003-2004 **Pharmacist**  
Department of Pharmacy, Riverside Methodist Hospital, Columbus, OH

- 2003-2004     **Pharmacist**  
The Kroger Company, Columbus, OH
- 1997-2002     **Pharmacy Intern**  
Drug Information Center, Ohio Northern University, Ada, OH

### **Education and Training**

- 2007-2009     **Master of Science, Clinical Research Design and Statistical Analysis**  
University of Michigan, School of Public Health, Ann Arbor, MI
- 2007-2009     **Clinical Research Training Program (K30)**  
University of Michigan, Medical School, Ann Arbor, MI  
Mentor: Keith Aaronson, MD, MS
- 2004-2005     **PGY2 Cardiology Specialty Residency, *ASHP accredited***  
University of North Carolina Hospitals, Chapel Hill, NC  
Program Directors: Debbie Montague, PharmD, MS  
Jo Ellen Rodgers, PharmD
- 2003-2004     **PGY1 Pharmacy Practice Residency, *ASHP accredited***  
Riverside Methodist Hospital, Columbus, OH  
Program Director: Rod Worsching, PharmD, FASHP
- 1997-2003     **Doctor of Pharmacy**  
Ohio Northern University, Ada, Ohio

### **Licensure**

- 2003-Present   Registered pharmacist, Ohio
- 2004-Present   Registered pharmacist, North Carolina
- 2005-Present   Registered pharmacist, Michigan

### **SCHOLARSHIP**

Narrative: My research program studies the effects of health information technology on outcomes in cardiovascular disease. This work includes patient and provider facing clinical decision support and adapts methods from behavioral health, computer science, data science and clinical translation. I have prospectively studied two mobile application-based just-in-time adaptive interventions (JITAI). One is a mobile application to support self-monitoring and self-management in heart failure. The other is mobile application that uses location aware services (including Wi-Fi, Bluetooth, accelerometer, gyroscope, magnetometer, and GPS) on the phone to reduce sodium intake when hypertensive patients shop at grocery stores and eat at restaurants. I have also begun to study provider facing applications in both anticoagulation and heart failure, which has led to internal and external funding. In addition to these technology-based interventions, I am passionate about research on appropriate medication therapy in cardiovascular disease. This is evident from my over 10 years of research publications in outcomes research on the topic. The following sections reflect my dedication to a sustainable research program and demonstrate my commitment to collaboration in team science.

### **Research Funding**

#### **Active**

Implementing Prescriber-Pharmacist Collaborative Care for Evidence-based Anticoagulant Use  
AHRQ R18 Total Award: \$1,300,000 09/30/2021 – 09/29/2024

Role: Co-Investigator (5%), Principal Investigator (Barnes)

Description: The major goals of this project are to (1) implement and evaluate an EHR medication alert system to improve safe DOAC prescribing through prescriber-pharmacist collaboration; (2) identify which patient and provider characteristics predict highest effectiveness of prescriber- vs. pharmacist-directed alerts; and (3) assess patient acceptance of and barriers to anticoagulation pharmacist involvement in medication changes.

A Just-In-Time Adaptive Mobile Application Intervention to Reduce Sodium Intake and Blood Pressure in Hypertensive Patients

NIH/NHLBI R61/R33 Total Award: \$3,887,135 09/15/2021 – 08/31/2026

Role: PI (20%), Co-PI - Nallamothu

Description: The of this proposal is to determine the efficacy of a mobile application based JITAI on blood pressure in a prospective clinical trial (LowSalt4Life 2).

Development and Implementation of a Digital Optimization Toolkit for Management of Heart Failure after Discharge - AHA HTI SFRN Supplement

AHA SFRN, Health IT Total Award: \$700,000 07/01/2021 – 06/30/2024

Role: PI (20%)

Description: This is a collaborative project among all AHA HTI SFRN Centers. The goal of this project is to create a toolkit synergized with American Heart Association guideline-based care to improve medical therapy and medication adherence to improve patient outcomes in post-discharge heart failure patients.

A multifaceted adaptive mobile application to promote self-management and improve outcomes in heart failure  
NIH/NIA R01 Total Award: \$3,067,380 04/15/2020 – 03/31/2025

Role: PI (25%)

Description: The goals of this proposal are to: (1) determine the impact of two unique adaptive mobile application interventions on HF readmission and health-related quality of life (HRQOL) in HF patients, (2) establish the effect the interventions have on proximal outcomes and that the proximal outcomes mediate the intervention's impact on HF readmission and HRQOL, and (3) develop data-driven machine learning models that can predict episodes of clinical worsening.

Wearables In Reducing risk and Enhancing Daily Life-style (WIRED-L)

AHA SFRN, Health IT Total Award: \$2,676,000 04/01/2020 – 03/31/2024

Role: PI (10%)

Description: The American Heart Association funded Stanford, Johns Hopkins, Cincinnati Children's Hospital and UM to participate in a Strategic Focused Research Network (SFRN) in health information technology. The initial UM goals of this project are 1) adapt two JITAIs to deliver tailored, contextually-rich behavior change messages to hypertension patients; 2) determine the effect of JITAIs on blood pressure over time in a large micro-randomized trial; and 3) expand our Center to develop future mHealth interventions in new conditions and at other SFRN sites. WIRED-L brings together multidisciplinary experts in cardiology, neurology, pharmacy, bioinformatics, biostatistics, computer science, health equity and business to create a reusable platform for studying mobile health (mHealth).

Improving Safe Use of Direct Oral Anticoagulants: A Population Health Approach

AHRQ R18 Total Award: \$1,499,506 04/01/2020 – 03/31/2023

Role: Co-Investigator (5%), Principal Investigator (Barnes)

Description: Findings from this study will lead to improvements in safe management and a reduction in adverse drug events for patients prescribed oral anticoagulant medications. This study will also identify important differences in the implementation approach for population health tools between fully integrated and traditional health systems.

#### Previous

A user-center designed anticoagulation shared decision-making tool for stroke prevention in atrial fibrillation  
AHRQ R21 Total Award: \$300,000 08/01/2019 – 07/31/2021

Role: PI (20%)

Description: The project will work with patients and providers to create a decision support tool that clarifies the risk tradeoffs for anticoagulation in AF, develop and implement a shared decision making support application based on the patient and provider feedback and determine if the new decision support tool with a value clarification facilitates patient knowledge compared to standard communication.

Real-world characteristics and treatment patterns among patients with venous thromboembolism within United States integrated delivery networks

Bristol-Myers Squibb Company Total Award: \$54,600 09/05/2019 – 09/04/2020

Role: PI (10%)

Description: The goal of this project is to determine the real-world effects of different anticoagulation practices in 4 integrated delivery networks.

Development of an EHR clinical decision support application to improve the safety and quality of heart failure care

UM MCubed Total Award: \$60,000 09/01/2018 – 12/31/2020

Role: PI (effort in kind)

Description: The goal of this project is to use qualitative and qualitative user centered design methods to create an electronic health record SMART on FHIR application for heart failure care.

Quantify Use of ANTicoagUlation to improve Management of AF (QUANTUM AF study)

DCRI/Johnson & Johnson 01/01/2017 – 12/31/2019

Role: Steering Committee, Principal Investigators (Hylek, Granger)

Description: This cluster randomized clinical trial will evaluate the effect of a structured hospital quality improvement program on oral anticoagulant (OAC) use in atrial fibrillation patients at 75 U.S. hospitals within the Premier health alliance.

Identification of Familial Hypercholesterolemia Patients in the University of Michigan Electronic Health Record.

Amgen, Inc. Total Award: \$187,037 09/01/2018 – 08/31/2019

Role: PI (10%)

Description: Validation of current computable algorithms for the identification of FH in the EHR.

A patient-centered mobile intervention to promote self-management and improve patient outcomes in chronic heart failure.

NIH/NIA R21 Total Award: \$426,250 09/01/2016 – 04/30/2019

Role: PI (20%)

Description: We tested the impact of a mobile application on clinical outcomes in HF, determine if novel pre-clinical measures predict clinical worsening in HF and develop messages for the mobile application.

A geofencing based adaptive messaging system to support patient self-management of a low sodium diet in hypertension.  
AHRQ R21 Total Award: \$299,622 05/03/2016 – 04/30/2019  
Role: PI (20%)  
Description: We developed and tested the effectiveness of a mobile application to help hypertensive patients reduce the amount of dietary sodium intake using mobile push notifications at grocery stores and restaurants.

A patient-centered mobile application for active and passive self-monitoring in heart failure.  
UM Frankel Cardiovascular Center Total Award: \$25,000 01/01/2014 – 12/31/2016  
Role: Co-Investigator (effort in kind), Principal Investigator (Koelling)  
Description: We further developed a mobile application for the self-monitoring and self-management of heart failure.

The validation of a novel adherence method for oral oncolytics.  
HOPA Total Award: \$47,500 01/01/2015 – 12/31/2015  
Role: Co-Investigator (5%), Principal Investigator (Kraft S)  
Description: In collaboration with iRxReminder, we investigated a health IT product to improve medication adherence in the patient's home.

MICHR Postdoctoral Translational Scholars Program – Aqeel Ahmed, Ph.D. (PI)  
Michigan Institute for Clinical and Health Research 01/01/2014 – 12/31/2015  
Role: Mentor (effort in kind)  
Description: Dr. Ahmed, a post-doctoral fellow in Dr. Carlson's lab, developed IT strategies to identify potential new targets for existing drug molecules. I served as Dr. Ahmed's mentor for health IT and clinical research.

Echocardiography supplement: The Effects of Vitamin D supplementation and Genetics on Biomarkers and Functional Status in Systolic Heart Failure.  
UM Frankel Cardiovascular Center Total Award: \$25,000 2010 – 2014  
Role: PI

The Effects of Vitamin D supplementation and Genetics on Biomarkers and Functional Status in Systolic Heart Failure.  
UM CTSA grant (UL1RR024986) Total Award: \$75,000 2009 – 2012  
Role: PI

**Publications (\* = for trainee)**

**Total Number of Peer-reviewed Publications: 76**

**Google Scholar Statistics**

Citations: 1438  
h-index: 18  
i10-index: 31

**Original Research Publications (\* = for trainee)**

52. Robles MC\*, Newman MW, Doshi A, Bailey S, Huang L, Choi SJ\*, Kurien C\*, Merid B\*, Cowdery J, Golbus JR, Huang C, **Dorsch MP**, Nallamotheu B, Skolarus LE. A Virtual, community-based participatory

design approach to a Physical Activity Just-in-Time Adaptive Intervention in Partnership with a Predominately Black Community: early-stage design. *JMIR Form Res.* 2022 Mar 28;6(3):e33087.

51. Barnes GD, Sippola E, Ranusch A, Takamine L, Lanham M, **Dorsch MP**, Sales A, Sussman J. Implementing an electronic health record dashboard for safe anticoagulant management: learning from qualitative interviews with existing and potential users to develop an implementation process. *Implement Sci Commun.* 2022;3(1):10.
50. Adie SK, Bitar A, Konerman MC, **Dorsch MP**, Andrews CA, Pogue KT, Park JM. Tacrolimus time in therapeutic range and long-term outcomes in heart transplant recipients. *Pharmacotherapy.* 2022 Feb;42(2):106-111.
49. Eze CE\*, West BT, **Dorsch MP**, Coe AB, Lester CA, Buis LR, Farris KB. Predictors of Smartphone and Tablet Use among Hypertensive Patients: A Secondary Analysis of HINTS Data. *J Med Internet Res.* 2022;24(1):e33188.
48. **Dorsch MP**, Farris KB, Rowell BE, Hummel SL, Koelling TM. The Effects of the ManageHF4Life Mobile Application on Patients With Chronic Heart Failure: Randomized Controlled Trial. *JMIR mHealth uHealth.* 2021 Dec 7;9(12):e26185. PMID: 34878990.
47. Campos-Staffico AM\*, Cordwin D\*, Murthy VL, **Dorsch MP**, Luzum JA. Comparative Performance of The Two Pooled Cohort Equations for Predicting Atherosclerotic Cardiovascular Disease. *Atherosclerosis.* 2021; 334:23-39.
46. Luzum JA, Edokobi O, **Dorsch MP**, Peterson E, Liu B, Gui H, Williams LK, Lanfear DE. Survival Association of Angiotensin Inhibitors in Heart Failure with Reduced Ejection Fraction: Comparisons Using Self-Identified Race and Genomic Ancestry. *J Card Fail.* 2021 Aug 20:S1071-9164(21)00338-9. Epub ahead of print. PMID: 34425222.
45. Campos-Staffico AM\*, Cordwin D\*, Ding Y, Lester CA, Brook RD, Luzum JA, **Dorsch MP**. Fewer patients receive recommendations for pharmacotherapy in primary prevention using the 2018 atherosclerotic cardiovascular disease risk estimator. *Prev Med.* 2021 Jul;148:106555. PMID: 33862035.
44. Chen C\*, Kim J, Guntupalli H, Garg N, Jagsi R, Griggs JJ, Sabel M, **Dorsch MP**, Callaghan B, Hertz DL. Chemotherapy-induced peripheral neuropathy detection via smartphone app: a cross-sectional pilot study. *JMIR mHealth and uHealth* 2021;9(7):e27502.
43. Compagner C\*, Lester CA, **Dorsch MP**. Sentiment Analysis of Online Reviews for Selective Serotonin Reuptake Inhibitors and Serotonin-Norepinephrine Reuptake Inhibitors. *Pharmacy.* 2021 Jan 23;9(1):27. PMID: 33498697.
42. Schaefer JK\*, Li M, Wu Z, Tanima Basu T, **Dorsch MP**, Barnes GD, Carrier M, Griggs JJ, Sood SL. Anticoagulant Medication Adherence for Cancer Associated Thrombosis: A Comparison of LMWH to DOACs. *J Thromb Haemost.* 2021;19(1):212-220.

41. Coe AB, Choe HM, Diez HL, Rockey NG, Ashjian EJ, **Dorsch MP**, Kim HM, Farris KB. Pharmacists providing care in statewide physician organizations: findings from the Michigan Pharmacists Transforming Care and Quality Collaborative. *J Manag Care Spec Pharm*. 2020;26(12):1558-66.
40. Schumacher L\*, Coe AB, Lester CA, Rothermal M, **Dorsch MP**. Factors that influence patient acceptance of clinical pharmacy services: A nationwide survey. *J Am Pharm Assoc (2003)*. 2020;60(6):1058-1067. PMID: 32962899.
39. Leino AD, **Dorsch MP**, Lester CA. Changes in Statin Utilization among US Adults with Diabetes: A Population-Based Analysis of NHANES 2011-2018. *Diabetes Care*. 2020;43(12):3110-3112.
38. Barnes GD, Sippola E, **Dorsch MP**, Errickson J, Lanham M, Allen A, Spoutz P, Sales A, Sussman J. Applying population health approaches to improve safe anticoagulant use in the outpatient setting: the DOAC Dashboard multi-cohort implementation evaluation study protocol. *Implement Sci*. 2020 Sep 21;15(1):83. PMID: 32958020.
37. Brinker LM, Konerman MC, Navid P, **Dorsch MP**, McNamara J, Willer CJ, Tinetti ME, Hummel SL, Goyal P. Complex and Potentially Harmful Medication Patterns in Heart Failure with Preserved Ejection Fraction. *Am J Med*. 2020 Aug 18:S0002-9343(20)30700-2. doi: 10.1016/j.amjmed.2020.07.023. Epub ahead of print.
36. **Dorsch MP**, Cornellier ML, Poggi AD, Bilgen F, Chen P, Wu C, An LC, Hummel SL. Effects of a Novel Contextual Just-In-Time Mobile App Intervention (LowSalt4Life) on Sodium Intake in Adults With Hypertension: Pilot Randomized Controlled Trial. *JMIR mHealth uHealth*. 2020;8(8):e16696.
35. Zheng Y\*, Jiang Y, **Dorsch MP**, Ding Y, Vydiswaran VGV, Lester CA. Work effort, readability and quality of pharmacy transcription of patient directions from electronic prescriptions: a retrospective observational cohort analysis. *BMJ Qual Saf*. 2020 May 25;. doi: 10.1136/bmjqs-2019-010405. [Epub ahead of print] PubMed PMID: 32451350.
34. Erickson SR, Basu T, **Dorsch MP**, Kamdar, N. Disparities in the Use of Guideline-Based Pharmacotherapy Exist for Atherosclerotic Cardiovascular Disease and Heart Failure Patients who have Intellectual/Developmental Disabilities in a Commercially Insured Database. *Ann Pharmacother*. 2020 Oct;54(10):958-966.
33. Hanigan S, Das J, Pogue K, Barnes GD, **Dorsch MP**. The real world use of combined P-glycoprotein and moderate CYP3A4 inhibitors with rivaroxaban or apixaban increases bleeding. *J Thromb Thrombolysis*. 2020 May;49(4):636-643.
32. **Dorsch MP**, Lester CA, Ding Y, Joseph M, Brook RD. Effects of Race on Statin Prescribing for Primary Prevention With High Atherosclerotic Cardiovascular Disease Risk in a Large Healthcare System. *J Am Heart Assoc*. 2019 Nov 19;8(22):e014709.
31. Adie S\*, Bitar A, Hanigan S, Pogue KT, Koelling TM, **Dorsch MP**. Real-world prevalence of adverse events after initiating sacubitril/valsartan compared to angiotensin converting enzyme inhibitors or angiotensin receptor blockers in systolic heart failure. *J Card Fail*. 2019 May;25(5):412-413.

30. Rollins A\*, Hanigan S, Pogue K, Renner E, Barnes G, **Dorsch MP**. Identifying Clinical Predictors of Switching From Direct Oral Anticoagulants to Warfarin. *Clinical Medicine Insights: Therapeutics*. 2019;11:1179559X19831287.
29. **Dorsch MP**, An LC, Hummel SL. A randomized controlled trial evaluating a novel just-in-time contextual mobile application intervention to reduce sodium intake in hypertension: Design and rationale for the LowSalt4Life trial. *JMIR Res Protoc*. 2018;7(12):e11282.
28. Bleske BE, Remington TL, Wells TD, Klein KC, **Dorsch MP**. A Randomized Crossover Comparison between Team-Based Learning and Lecture Format on Long-Term Learning Outcomes. *Pharmacy* 2018 Aug 4;6(3). pii: E81. doi: 10.3390/pharmacy6030081.
27. Remington TL, Bleske BE, Bartholomew T, **Dorsch MP**, Guthrie SK, Klein KC, Tingen JM, Wells TD. Qualitative Analysis of Student Perceptions Comparing Team-based Learning and Traditional Lecture in a Pharmacotherapeutics Course. *Am J Pharm Educ*. 2017 Apr;81(3):55.
26. Bleske BE, Remington TL, Wells TD, Klein KC, Guthrie SK, Tingen JM, Marshall VD, **Dorsch MP**. A Randomized Crossover Comparison of Team-based Learning and Lecture Format on Learning Outcomes. *Am J Pharm Educ*. 2016 Sep 25;80(7):120.
25. Early CR\*, Park JM, **Dorsch MP**, Pogue KT, Hanigan S. Effect of Metronidazole Use on Tacrolimus Concentrations in Transplant Patients Treated for Clostridium difficile. *Transpl Infect Dis*. 2016 Oct;18(5):714-720.
24. Albabtain M\*, Brenner MJ, Nicklas JM, Hummel SL, McCormick MP, Remington TL, Gure TR, **Dorsch MP**, Bleske BE. Hyponatremia, Cognitive Function, and Mobility in an Outpatient Heart Failure Population. *Med Sci Monit*. 2016 Dec 18;22:4978-4985.
23. Erickson SR, Spoutz P, **Dorsch MP**, Bleske BE. Cardiovascular risk and treatment for adults with intellectual or developmental disabilities. *Int J Cardiol*. 2016 Jul 5;221:371-375.
22. Ha NB\*, Yang K, Hanigan S, Kurtz B, **Dorsch MP**, Mak H, Nagel J. Impact of a Guideline for the Management of Antimicrobial/Warfarin Interactions in the Inpatient Setting and Across Transition of Care. *Ann Pharmacother*. 2016 Sep;50(9):734-40.
21. Kaminsky B\*, Pogue KT, Hanigan S, Koelling TK, **Dorsch MP**. Effects of Total Dose Infusion of Iron Intravenously in Patients with Acute Heart Failure and Anemia (Hemoglobin < 13 g/dL). *Am J Cardiol*. 2016 Jun 15;117(12):1942-6.
20. Vu NH, Jaynes E, Chan C, **Dorsch MP**, Pipe S, Alaniz C. Argatroban Monitoring: aPTT versus Chromogenic Assay. *Am J Hematol*. 2016 Jun;91(6):E303-4.
19. **Dorsch MP**, Chong YP, McCormick MP, Grossi J, Farris KB, Koelling TM, Bleske BE. Survey of Computer, Smart Devices, and Internet use in Heart Failure Patients. *International Cardiovascular Forum Journal*. 2016;6:84-85.



18. Scherkenbach LA\*, Kraft MD, Stout SM, **Dorsch MP**, Chen X, Tran H, Pleva MR. Impact of an Intravenous Magnesium Shortage on Potassium Doses in Adult Surgical Patients Receiving Parenteral Nutrition. *JPEN J Parenter Enteral Nutr*. February 5, 2015. [Epub ahead of print]
17. **Dorsch MP**, Farris KB, Bleske BE, Koelling TM. A web application for self-monitoring improves symptoms in chronic systolic heart failure. *Telemed J E Health*. 2015;21(4):267-70.
16. Lose JM\*, **Dorsch MP**, DiDomenico RJ. Comparison of practice patterns between inpatient cardiology pharmacists with and without added qualifications in cardiology. *Hosp Pharm*. 2015 Jan;50(1):51-8.
15. Bleske BE, Dillman NO, Cornelius D, Ward JK, Burson SC, Diez HL, Pickworth KK, Bennett MS, Nicklas JM, **Dorsch MP**. Heart failure assessment at the community pharmacy level: a feasibility pilot study. *J Am Pharm Assoc*. 2014 Nov-Dec;54(6):634-41.
14. **Dorsch MP**, Lose JM\*, DiDomenico RJ. The Effect of Cardiovascular Credentialed Pharmacists on Process Measures and Outcomes in Myocardial Infarction and Heart Failure. *Pharmacotherapy*. 2014 Aug;34(8):803-8.
13. Bleske BE, Remington TL, Wells TD, **Dorsch MP**, Guthrie SK, Stumpf JL, Alaniz MC, Ellingrod VL, Tingen JM. Team-based learning to improve learning outcomes in a therapeutics course sequence. *Am J Pharm Educ*. 2014 Feb 12;78(1):13.
12. **Dorsch MP**, Nemerovski CW\*, Ellingrod V, Cowger CA, Dyke DB, Koelling TM, Wu AH, Simpson RU, Bleske BE. Vitamin D Receptor Genetics on Extracellular Matrix Biomarkers and Hemodynamics in Systolic Heart Failure. *J Cardiovasc Pharmacol Ther* 2014 Sep;19(5):439-45.
11. Shuster JE\*, **Dorsch MP**. Utilization of a Computerized Clinical Surveillance System to Increase Acute Myocardial Infarction Core Measure Compliance. *Hosp Pharm* 2014; 49 (1): 1-6.
10. Lose JM\*, **Dorsch MP**, Stevenson JG. Cost Containment for Argatroban Through Reduction in Drug Waste: Experience at a Single Center. *Pharmacy Times* March 2013 Supplement: 1-4.
9. Clarke MM\*, **Dorsch MP**, Kim S, Aaronson KD, Koelling TM, Bleske BE. Baseline Albumin Is Associated with Worsening Renal Function in Patients with Acute Decompensated Heart Failure Receiving Continuous Infusion Loop Diuretics. *Pharmacotherapy*. 2013;33(6):583-8.
8. Bleske BE, Clark MM\*, Wu AH, **Dorsch MP**. The Effect of Continuous Infusion Loop Diuretics in Patients With Acute Decompensated Heart Failure With Hypoalbuminemia. *J Cardiovasc Pharmacol Ther* 2013 Jul;18(4):334-7.
7. Pettit RS\*, Zimmerman CR, Alaniz C, **Dorsch MP**. Cost Analysis Before and After Implementation of a Computerized Physician Order Entry Order Form for Enoxaparin. *Pharmacy and Therapeutics* 2012. 37 (2): 107-111.
6. Carroll N\*, **Dorsch MP**. Cost Implications of Providing Discharge Supplies of Antiplatelet Medication to PCI Patients. *Am J Manag Care*. 2011;17(12):803-810.

5. **Dorsch MP**, Gillespie BW, Erickson SR, Bleske BE, Weder AB. Chlorthalidone reduces cardiovascular events compared to hydrochlorothiazide: A retrospective cohort analysis. *Hypertension* 2011 Apr;57(4):689-94.
4. Nicolasora NP, Malani PN, Riddell J, **Dorsch MP**, Reaume KT\*, Dyke DB, Pagani FD, Aaronson KD, Kaul DR. Opportunistic infections in heart transplant patients: The role of thymoglobulin and corticosteroid dosing. *Infect Dis Clin Pract* 2010; 18:318-23.
3. Booher AM, **Dorsch MP**, Gurm HS. Case report: the effect of proton pump inhibitor administration on hemodynamics in a cardiac intensive care unit. *Clin Cardiol* 2010; 33(6):E111-
2. Reaume KT\*, Erickson SR, **Dorsch MP**, Dunham NL, Hiniker SM, Prabhakar, N, Kline-Rogers EM, Eagle KA. Effects of cerivastatin withdrawal on statin persistence. *Ann Pharmacother* 2008; Jul;42(7):956-61.
1. **Dorsch MP**, Lee JS, Lynch DR, Dunn SP, Rodgers JE, Schwartz T, Colby E, Montague D, Smyth SS. Aspirin resistance in patients with stable coronary artery disease with and without a history of myocardial infarction. *Ann Pharmaother* 2007; 41: 737-41.

Peer-Reviewed Manuscripts – Reviews (\* = for trainee)

23. Krishnaswami A, Beavers C, **Dorsch MP**, Dodson JA, Masterson Creber R, Kitsiou S, Goyal P, Maurer MS, Wenger NK, Croy DS, Alexander KP, Batsis JS, Turakhia MP, Forman DE, Bernacki GM, Kirkpatrick JN, Orr NM, Peterson ED, Rich MW, Freeman AM, Bhavnani SP. Challenges and Opportunities Of Gerotechnology For The Prevention And Treatment Of Cardiovascular Disease In Older Adults. *J Am Coll Cardiol* 2020;76:2650-70.
22. Lester CA, Coe AB, **Dorsch MP**, Farris KB, Flynn AJ. A learning pharmacy practice enabled by the pharmacists' patient care process. *J Am Pharm Assoc* (2003). 2020 2020, 60(6), pp. e66–e72. PMID: 32620363.
21. Haase J\*, Farris KB, **Dorsch MP**. Mobile Applications to Improve Medication Adherence. *Telemed J E Health*. 2017 Feb;23(2):75-79.
20. Jimbo M, **Dorsch MP**, Ealovega MW, Harrison RV, Jamerson KA. Essential Hypertension. Ann Arbor, MI: Quality Department, University of Michigan Health System, 2014. [Available at <http://www.uofmhealth.org/provider/clinical-care-guidelines>] [practice guideline].
19. Walter CP\*, Bleske BE, **Dorsch MP**. Pharmacotherapy for weight loss: the cardiovascular effects of the old and new agents. *J Clin Pharm Ther*. 2014 Oct;39(5):475-84.
18. Lose JM\*, Bleske B, **Dorsch MP**. Evaluation of proprotein convertase subtilisin kexin type 9: focus on potential clinical and therapeutic implications for LDL cholesterol lowering. *Pharmacotherapy*. 2013 Apr;33(4):447-60.

17. Shuster JE\*, Bleske BE, **Dorsch MP**. Clinical utility of azilsartan–chlorthalidone fixed combination in the management of hypertension. *Vascular Health and Risk Management* 2012. 8 (1): 381-7.
16. Barnes MM\*, **Dorsch MP**, Hummel SL, Koelling TM, Bleske BE. Treatment of heart failure with preserved ejection fraction. *Pharmacotherapy* 2011; 31(3):312-31.
15. Nemerovski CW, **Dorsch MP**, Jennings DL. What Should We Be Fine Tuning in Acute Coronary Syndromes - Dosing of Antiplatelet Therapy or Data Presentation? *Ann Pharmacother* 2011; 45: 120-122.
14. Mohammad RA, Goldberg T, **Dorsch MP**, Cheng JWM. Antiplatelet Therapy After Drug-Eluting Stent Placement: A Narrative Review. *Clin Ther* 2010; 32 (14): 2265-81.
13. Momary KM, **Dorsch MP**. Factors associated with clopidogrel nonresponsiveness. *Future Cardiol* 2010; 6 (2):195-210.
12. Momary KM, **Dorsch MP**, Bates ER. Genetic causes of clopidogrel nonresponsiveness: which ones really count? *Pharmacotherapy* 2010; 30 (3):265-74.
11. Chow SL, **Dorsch MP**, Dunn SP, Jackevicius CA, Page RL, Trujillo T, Vardeny O, Wiggins B, Bleske BE. Key articles related to complementary and alternative medicine in cardiovascular disease: part 1. *Pharmacotherapy* 2010; 30 (1):109.
10. Jimbo M, Barrie WE, **Dorsch MP**, Harrison RV, Jamerson KA. Essential Hypertension. Ann Arbor, MI: Office of Clinical Affairs, University of Michigan Health System, 2009. [Available from the Agency for Healthcare Research and Quality at [www.guideline.gov](http://www.guideline.gov) and from UMHS at [www.med.umich.edu/1info/fhp/practiceguides](http://www.med.umich.edu/1info/fhp/practiceguides)] [practice guideline]
9. Nemerovski, CW\*, **Dorsch MP**, Simpson RU, Bone HG, Aaronson K and Bleske BE. Vitamin D and Cardiovascular Disease. *Pharmacotherapy* 2009; 29 (6): 691–708.
8. Dunn SP, Bleske BE, **Dorsch MP**, Macaulay T, Van Tassell B, Vardeny O. Nutrition and Heart Failure: Impact of Drug Therapies and Management Strategies. *Nutr Clin Pract* 2009; 24: 60-75.
7. Matthews JC, Dardas TF, **Dorsch MP**, Aaronson KD. Right-sided heart failure: diagnosis and treatment strategies. *Curr Treat Options Cardiovasc Med* 2008;10:329-41.
6. Reaume KT\*, Regal RE, **Dorsch MP**. Indications for dual antiplatelet therapy with aspirin and clopidogrel: evidence-based recommendations for use. *Ann Pharmacother* 2008; 42: 550-7.
5. Butler SO, **Dorsch MP**. Antifibrinolytic agents in coronary artery bypass graft surgery. UHC Drug Monograph, March 2007.
4. **Dorsch MP**, Rodgers JE. Nesiritide – Harmful or Harmless. *Pharmacotherapy* 2006; 26 (10): 1465-1478.

3. **Dorsch MP**, Dunn SP. Antiplatelet drug resistance: almost ready for prime time. *Pharmacotherapy* 2006; 26 (8): 1201-1202.
2. **Dorsch MP**, Montague D, Rodgers, JE, Patterson C. Abciximab-associated thrombocytopenia after previous tirofiban-related thrombocytopenia. *Pharmacotherapy* 2006; 26 (3): 423-427.
1. Denucci K, **Dorsch MP**, Sweeney M. Bringing knowledge to the community, *Ohio Pharmacist* May 2003.

#### Peer-Reviewed Manuscripts – Invited Editorials

1. Dardas T, **Dorsch MP**. Remote management of heart failure: Herculean or Sisyphean task? *Heart*. 2020 Oct;106 (20):1543-1544.

#### Peer-Reviewed Book Chapters

**Dorsch MP**, Pogue KT. Newer Antithrombotic Agents and Their Role in Acute Coronary Syndrome. Pharmacy Self-Assessment Program. Book 1 Cardiology/Endocrinology. Release 2013.

#### Presentations

- Spring 2022 **Decision algorithms to support student learning about self-care therapeutics**  
American Association of Colleges of Pharmacy, Self-care Therapeutics SIG
- Fall 2021 **Just-in-time adaptive interventions for sodium intake – LowSalt4Life**  
Centre for Health Informatics, Digital Health Reading and Research Group, University of Manchester, Manchester, England
- Fall 2021 **Just-in-time adaptive interventions (JITAI) and Microrandomized trials (MRT) in mHealth**  
American Heart Association, Quality of Care and Outcomes Research Annual Meeting
- Spring 2021 **Patient-centered clinical decision support in Heart Failure**  
4<sup>th</sup> National Taiwan University School of Pharmacy Research Day and International Conference, Taipei, Taiwan (Virtual)
- Winter 2021 **Mobile Technology and Wearables for Heart Failure Patient Management**  
Heart Failure Society of America, Patient Podcast
- Spring 2019 **Patient-centered clinical decision support: A case for precision health**  
Precision Health Initiative Conference, University of Michigan
- Spring 2018 **Heart Failure 101: The Pharmacists Role**  
Michigan Pharmacists Transforming Care and Quality Meeting
- Winter 2017 **Mobile Health Technologies in Cardiovascular Disease**  
Learning Health System Collaboratory, Medical School, University of Michigan
- Fall 2016 **Hyperkalemia: Implication for HF Management (Moderator)**  
Heart Failure Society of America Annual Scientific Meeting

- Fall 2015 **Innovations in Practice Technology (Discussant)**  
American College of Clinical Pharmacy Annual Meeting
- Fall 2015 **Clinical Reasoning Series: Heart Failure: Current and Emerging Management Strategies**  
American College of Clinical Pharmacy Annual Meeting
- Fall 2015 **Reduction in Heart Failure Readmissions – Medication Reconciliation**  
American College of Cardiology, Michigan Chapter Annual Meeting
- Spring 2014 **Integration of IPPE and APPE students into an inpatient service**  
Michigan Pharmacists Association Annual Meeting
- Spring 2013 **Novel Anticoagulants and Antithrombotics: Atrial Fibrillation**  
Society of Vascular Medicine Annual Meeting
- Fall 2012 **Using IT to Make Your Work as a Pharmacist More Efficient**  
MSHP Annual Meeting
- Fall 2012 **Establishing a Role for New Oral Anticoagulants**  
University of Michigan College of Pharmacy Annual Pharmacy Lectures
- Fall 2012 **To Replace Clopidogrel or Not? The Case for Clopidogrel Only**  
American College of Clinical Pharmacy Annual Meeting
- Fall 2011 **Update on Hyponatremia**  
American College of Clinical Pharmacy Cardiology PRN Business Meeting
- Fall 2011 **The Use of TheraDoc® in Research**  
Grand Rounds, University of Michigan Department of Pharmacy
- Summer 2009 **Are Clopidogrel's Kinetics a Catastrophe?**  
Grand Rounds, University of Michigan Department of Pharmacy
- Winter 2008 **Integrating Treatment Guidelines for ACS into Clinical Practice: Antiplatelet and Anticoagulant Therapies**  
ASHP Midyear Meeting
- Spring 2008 **Meeting the Needs of Patients with Acute Severe Hypertension: Current Practices, Future Directions**  
ASHP Annual Meeting
- Winter 2008 **Acute Cardiac Life Support – Case Based Discussion**  
Grand Rounds, University of Michigan Department of Pharmacy
- Fall 2007 **Comorbidities of Uncontrolled Hypertension: Reducing Risks and Burden**  
American College of Clinical Pharmacy Annual Meeting and Webcast

- Spring 2007 **Debating Long Term Antithrombotic Therapy-Interpreting Registries, Trials and Current Practice Patterns**  
AMCP Annual Meeting and Webcast
- Winter 2007 **A Review of the "New" Guidelines in the Management of Heart Failure**  
University of Michigan Department of Pharmacy
- Fall 2006 **Pitfalls with Inpatient Cardiovascular Drug Therapies: From pharmacokinetics, dynamics and genomics to common myths in inpatient drug use**  
Cardiovascular Medicine Grand Rounds, University of Michigan Cardiovascular Center
- Fall 2006 **Incorporating the Guidelines: Case Studies**  
Cardiology PRN Pre-symposium, ACCP Annual Meeting
- Summer 2006 **Treatment of Acute Decompensated Heart Failure**  
University of Michigan Cardiovascular Center, Symposium for Nurses
- Spring 2005 **An Update on the Management of Heart Failure**  
UNC Hospitals, Department of Pharmacy
- Winter 2005 **Pharmacology of Ischemic Heart Disease**  
University of North Carolina, School of Pharmacy
- Fall 2004 **The Vasopressin Receptor: A New Target in Heart Failure**  
UNC Hospitals, Department of Pharmacy
- Fall 2004 **Pharmacokinetics and Drug Delivery**  
University of North Carolina, School of Nursing
- Fall 2004 **Overview of Cardiovascular Medications: Implications for Dentists**  
University of North Carolina, School of Dentistry
- Spring 2004 **Medications and the Older Adult**  
Central Ohio Area Agency on Aging Annual Meeting
- Winter 2003 **Drug Information: What is Available?**  
Riverside Methodist Hospital, Department of Pharmacy Services
- Fall 2003 **Argatroban: What a Nurse Needs to Know**  
Riverside Methodist Hospital
- Spring 2003 **Heart Failure**  
Ohio Northern University, Department of Pharmacy Practice
- Spring 2003 **Acute Heart Failure**  
Ohio Northern University, Department of Pharmacy Practice

## **TEACHING**

### **Undergraduate**

2020-Present Precision Health Elective – Health IT (Teacher)

### **Doctor of Pharmacy**

2018-Present Medicinal Chemistry, Cardiology Capstone (Teacher)  
2018 Evidence Based Medicine  
2013-2015 PharmD Investigations (Course Coordinator)  
2011-Present Therapeutic Problem Solving (Course Coordinator and Teacher)  
2011-2012 Principles of Research and Problem Solving  
2008-Present PharmD Investigations (Independent Study)  
2007-Present Research (Independent Study)  
2006-2011 Pathophysiology and Therapeutics (Teacher)

### **Doctor of Pharmacy, Experiential Education**

2006-2018 Inpatient Cardiology P4 APPE (Primary or Secondary preceptor for 10-15 students/year)  
2014-2018 Inpatient P3 IPPE (Primary or Secondary preceptor for 1-3 students/year)

### **Doctor of Philosophy in Clinical Pharmacy Translational Science**

2018-Present Pharmacy Informatics  
2018-2020 Grant Writing, Part 2 (Co-coordinate)

### **Pharmacy Resident Research Series, Michigan Medicine**

2009-2017 Statistical Power  
2009-2017 Data Analysis

### **UM Division of Cardiovascular Medicine, Cardiology Fellowship**

2009-2017 Antiadrenergic agents in Chronic Heart Failure

### **PGY2 Cardiology Residency Program Director, Michigan Medicine**

Kristen Pogue, PharmD, BCPS (AQ CV) (2007-2008); Carrie Nemerovski, PharmD, BCPS (AQ CV) (2008-2009); Megan Barnes, PharmD, BCPS (AQ CV) (2009-2010); Jennifer Lose, PharmD, BCPS (2011-2012); Jerrica Shuster, PharmD, BCPS (2011-2012); Claire Walter, PharmD, BCPS (2012-2013); Brad Williams, PharmD, BCPS (2013-2014); Denise Sutter, PharmD, BCPS (2014-2015); Bonnie Kaminsky, PharmD, BCPS (2015-2016); Monique Conway, PharmD, BCPS (2016-2017); Sarah Adie, PharmD (2017-2018)

### **Cardiovascular Research Fellowship Director, College of Pharmacy, University of Michigan**

David Cordwin, PharmD (2020-2021)

## **SERVICE**

### **Professional Service - Local**

#### **University of Michigan Hospitals and Health System**

2015-2018 Member, Anticoagulation Subcommittee, Pharmacy and Therapeutics Committee  
2010-2015 Co-chair, Anticoagulation Subcommittee, Pharmacy and Therapeutics Committee  
2011-2017 Member, Pharmacy Practice Model Steering Committee

2009-2010 Secretary, Anticoagulation Subcommittee, Pharmacy and Therapeutics Committee

University of Michigan College of Pharmacy

2018-Present Founding Member, Pharmacy INformatics Group (PING)  
2018-Present Member, ExamSoft Implementation Team (ExSIT)  
2017-Present Member, Therapeutics Problem Solving Course Coordinators  
2013-2014 Chair, PharmD Investigations Steering Committee  
2013-2015 Chair, PharmD Investigations Committee  
2010-2011 Member, Evidence Based Medicine Subcommittee, Curriculum Committee  
2008-2018 Member, Residency Advisory Committee

**Professional Service - National**

Professional Organizations

2016-Present **American College of Cardiology**  
2007-2014 **National Lipid Association**  
2005-Present **American Heart Association**

- ACC/AHA Task Force on Performance Measures (2021-Present)

2004-Present **American College of Clinical Pharmacy**

- Cardiology PRN
  - Committee Chair for Young Investigator Research Presentations (2006-2011)
- Member Relations Ad Hoc Committee on Volunteer Recognition (2010-2012)
- PBRN Community Advisory Panel, ACCP Research Institute (2016-2018)
- University of Michigan Faculty Liaison (2019-Present)

**Certificates, Honors and Awards**

2022 **Fellow, American College of Cardiology (FACC)**  
American College of Cardiology

2019 **Mentoring Award**  
American College of Clinical Pharmacy, Cardiology Practice and Research Network

2018-Present **Board-Certified Cardiology Pharmacist (BCCP)** – replaces AQ Cardiology  
Board of Pharmaceutical Specialties

2016 **Fellow, American Heart Association (FAHA)**  
American Heart Association, Council on Quality of Care and Outcomes Research

2016 **Professional Practice Award**  
Michigan Society of Health-System Pharmacists

2016 **Member, Institute for Health Policy and Innovation**  
University of Michigan

2015 **Fellow, American College of Clinical Pharmacy (FCCP)**  
American College of Clinical Pharmacy Annual Meeting

2015 **Essential Skills for Successful Leadership**



University of Michigan Medical School

- 2012      **Top Paper Award for Population Science in 2011**  
*Hypertension*, 66<sup>th</sup> Annual Meeting of the American Heart Association Council for High Blood Pressure Research Conference
- 2012      **Role Delineation Study Member, Cardiology Specialty**  
Board of Pharmacy Specialties
- 2011      **Making A Difference Award**  
University of Michigan Hospitals and Health Centers
- 2011      **Teaching Recognition Award – P3 class**  
Phi Delta Chi, University of Michigan, College of Pharmacy
- 2008      **Member, Cardiovascular Center**  
University of Michigan
- 2008      **Teaching Recognition Award – P3 class**  
Phi Delta Chi, University of Michigan, College of Pharmacy
- 2007-2018      **Added Qualifications in Cardiology**  
Board of Pharmaceutical Specialties
- 2005, 2006      **Your Super Award**  
University of Michigan Hospitals and Health Centers
- 2004-2018      **Board Certified Pharmacotherapy Specialist**  
Board of Pharmaceutical Specialties
- 2003      **Student Service and Leadership Award**  
Council of Ohio Colleges of Pharmacy
- 2002      **APhA-ASP Senior Recognition Award**  
Ohio Northern University
- 2001      **ONU Pharmacy Faculty Award**  
Ohio Northern University

**Reviewer/Editor**

**Manuscript Referee**

American Journal of Cardiovascular Drugs  
Annals of Internal Medicine  
Circulation  
Circulation: Heart Failure  
Circulation: Cardiovascular Quality and Outcomes  
Expert Review of Cardiovascular Therapy

Future Cardiology  
Future Medicine  
Journal of the American College of Clinical Pharmacy  
Journal of Cardiac Failure  
Journal of Clinical Pharmacology  
Journal of Medical Internet Research (JMIR)  
JMIR Cardio  
JMIR Protocols  
Journal of Pharmacy Practice  
Journal of Telemedicine and Telecare  
Journal of the American Heart Association  
Pharmacotherapy  
Telemedicine and e-Health  
The American Journal of Cardiology  
The Lancet  
Therapeutic Delivery  
Thrombosis Research

Guest Editor

PLOS Digital Health

Book/Book Chapter Review

Cardiovascular Pharmacotherapy: A Point-of-care Guide  
Updates in Therapeutics: The Pharmacotherapy Preparatory Course, 2009 Edition  
Pharmacy Self-Assessment Program – Cardiology 2009  
Pharmacy Self-Assessment Program – Economics and Patient-Centered Outcomes Assessment 2014

Honorary Affiliations

2002-2003     **Omicron Delta Kappa** – National Leadership Honor Society  
                  Ohio Northern University

2001-2003     **Phi Lambda Sigma** – National Pharmacy Leadership Honor Society  
                  College of Pharmacy, Ohio Northern University

Updated: 4/22